Trial Profile
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Zetomipzomib (Primary) ; Zetomipzomib (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Kezar Life Sciences
- 26 Mar 2019 According to a Kezar Life Sciences media release, data from this trial may support development and potential regulatory approval.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 08 Nov 2017 Results assessing safety, pharmacokinetics and pharmacodynamics of KZR-61 presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting